Key result
High VTE risk score linked to ~7-fold higher early mortality in cancer patients initiating chemotherapy.
Why the study?
Venous thromboembolism is a common complication in cancer patients receiving chemotherapy and is strongly associated with early all-cause mortality, but the predictive ability of a VTE risk model for disease progression and early mortality needed evaluation.
Does a VTE risk model predict disease progression and early all-cause mortality in adult cancer patients initiating chemotherapy?
Population
4,458 adult cancer patients with solid tumors or malignant lymphoma initiating chemotherapy in the USA
Comparison
Intermediate and high VTE risk groups (II and III) versus low risk group (I)
Design
Prospective cohort study at 115 randomly selected practice sites
Follow-up
4 months
Authors
Loading...
Supports VTE risk stratification for mortality prognostication in chemotherapy patients; leaves open prospective validation and intervention trials.
Cohort (n=4,458)
Yes
Does a VTE risk model predict disease progression and early all-cause mortality in adult cancer patients initiating chemotherapy?
Hazard Ratio: 6.89 (95% CI 3.5–13.57)
Absolute Event Rate: 12.7% vs 1.2%
p-value: p=<0.0001
A validated VTE risk model strongly predicts not only VTE occurrence but also early disease progression and overall mortality in cancer patients starting chemotherapy.
Kuderer et al. (2008) conducted a cohort in Cancer (solid tumors or malignant lymphoma) (n=4,458). High VTE risk score (Group III) vs. Low VTE risk score (Group I) was evaluated on Death from all causes within 4 months (HR 6.89, 95% CI 3.50-13.57, p=<0.0001). A high VTE risk score was strongly associated with increased early all-cause mortality compared to a low risk score in cancer patients initiating chemotherapy (HR 6.89; 95% CI 3.50-13.57; P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: